Standard escalation follows: 0.25mg weeks 1-4, 0.5mg weeks 5-8, 1.0mg weeks 9-12, with potential further increases to 1.7mg or 2.4mg based on response
In case of CKD, the use of a GLP-1RA with proven cardiovascular benefit is only recommended in those who have not achieved individualized glycemic targets despite SGLT2i treatment, or in whom SGLT2is are contraindicated or not tolerated [6, 8]
Personalized GLP-1 Dosing Strategies Beyond Standard Wegovy PlexusDx recognizes that weight loss is not one-size-fits-all, which is why personalized compounding allows your practitioner to tailor both dose strength and injection frequency to your body's response
Taking new patients and accepting most insurance plans, including Medicare
7 adverse events were ongoing at the end of the study, all in the liraglutide arm
This new grant is the latest project in nearly 15 years of research by Stokes and colleagues on the health consequences of obesity and disparities in access to obesity-related healthcare in the U.S